BDTX RSI Chart
Last 7 days
11.8%
Last 30 days
20%
Last 90 days
102.8%
Trailing 12 Months
305.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 2.3M | 0 | 0 | 1.9M |
2022 | 2.7M | 0 | 2.3M | 2.2M |
2021 | 4.4M | 4.5M | 4.1M | 3.5M |
2020 | 1.2M | 2.1M | 3.2M | 4.0M |
2019 | 0 | 0 | 0 | 461.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 15, 2024 | behbahani ali | acquired | 14,373 | 4.54 | 3,166 | - |
Mar 15, 2024 | dixon wendy l | acquired | 14,768 | 4.54 | 3,253 | - |
Dec 15, 2023 | behbahani ali | acquired | 12,162 | 2.73 | 4,455 | - |
Dec 15, 2023 | dixon wendy l | acquired | 11,037 | 2.73 | 4,043 | - |
Oct 17, 2023 | biotech growth n v | bought | 934,080 | 2.3352 | 400,000 | - |
Sep 15, 2023 | velleca mark a. | acquired | 18,748 | 3.6 | 5,208 | president & ceo |
Sep 15, 2023 | behbahani ali | acquired | 11,876 | 3.6 | 3,299 | - |
Sep 15, 2023 | dixon wendy l | acquired | 10,749 | 3.6 | 2,986 | - |
Jul 05, 2023 | ra capital management, l.p. | bought | 4,679,250 | 5.00 | 935,850 | - |
Jul 05, 2023 | behbahani ali | bought | 5,000,000 | 5.00 | 1,000,000 | - |
Which funds bought or sold BDTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | SIMPLEX TRADING, LLC | added | 3,215 | 37,000 | 37,000 | -% |
Apr 22, 2024 | Raymond James Financial Services Advisors, Inc. | new | - | 87,417 | 87,417 | -% |
Apr 22, 2024 | HERBST GROUP, LLC | sold off | -100 | -38,314 | - | -% |
Apr 22, 2024 | RAYMOND JAMES & ASSOCIATES | new | - | 119,829 | 119,829 | -% |
Apr 19, 2024 | Cutler Group LLC / CA | added | 16.67 | 2,000 | 3,000 | -% |
Apr 16, 2024 | TSFG, LLC | unchanged | - | 1,000 | 1,000 | -% |
Apr 15, 2024 | Palumbo Wealth Management LLC | new | - | 51,933 | 51,933 | 0.02% |
Apr 12, 2024 | DLK Investment Management, LLC | unchanged | - | 36,646 | 82,210 | 0.04% |
Apr 05, 2024 | CWM, LLC | unchanged | - | - | - | -% |
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | unchanged | - | -60.00 | 2,810 | -% |
Unveiling Black Diamond Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Black Diamond Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.75 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.0B | 1.8B | -41 | 9.87 | ||||
BMRN | 15.4B | 2.5B | 74.73 | 6.21 | ||||
INCY | 11.6B | 3.7B | 19.41 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 6.0B | 396.6M | -11.37 | 15.16 | ||||
BBIO | 4.4B | - | -6.7 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.22 | 12.57 | ||||
ACAD | 2.8B | 726.4M | -44.9 | 3.79 | ||||
ARWR | 2.7B | 240.7M | -9.23 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.58 | 4.41 | ||||
NVAX | 569.6M | 983.7M | -1.05 | 0.58 | ||||
CRBP | 361.2M | 881.7K | -8.1 | 466.16 | ||||
INO | 247.0M | 4.9M | -1.83 | 50.76 | ||||
IBIO | 6.1M | 2.1M | -0.22 | 2.14 |
Black Diamond Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -100.0% | - | 622 | 677 | 562 | 406 | 588 | 776 | 948 | 1,152 | 1,254 | 1,162 | 881 | 744 | 440 | 1.00 | 9.00 | 11.00 |
Operating Expenses | -3.3% | 20,855 | 21,561 | 21,852 | 22,124 | 25,679 | 26,080 | 35,364 | 34,715 | 30,713 | 23,183 | 18,480 | 15,028 | 12,879 | 10,344 | 8,148 | 6,999 | 3,841 |
S&GA Expenses | -18.2% | 5,566 | 6,808 | 7,243 | 6,277 | 7,893 | 6,416 | 7,738 | 7,996 | 7,893 | 5,427 | 5,551 | 4,858 | 5,525 | 2,884 | 2,514 | 1,353 | 828 |
R&D Expenses | 3.6% | 15,289 | 14,753 | 14,609 | 15,847 | 17,786 | 19,664 | 27,626 | 26,719 | 22,820 | 17,756 | 12,929 | 10,170 | 7,354 | 7,460 | 5,634 | 5,646 | 3,013 |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 1.00 | - | - | - | - | - |
Net Income | 7.0% | -19,408 | -20,875 | -21,078 | -21,654 | -25,507 | -25,867 | -35,077 | -34,351 | -30,301 | -22,626 | -17,912 | -14,571 | -12,145 | -9,875 | -9,268 | -12,287 | -3,828 |
Net Income Margin | -12.3% | -42.85* | -38.17* | -40.83* | -41.15* | -44.45* | -36.26* | -29.63* | -23.29* | -19.20* | - | - | - | - | - | - | - | - |
Free Cashflow | 30.3% | -13,956 | -20,031 | -21,939 | -16,468 | -28,607 | -24,379 | -27,971 | -26,013 | -24,495 | - | - | - | - | - | - | - | - |
Balance Sheet | |||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
Assets | -8.0% | 159 | 172 | 120 | 136 | 156 | 180 | 199 | 219 | 248 | 274 | 288 | 313 | 330 | 346 | 349 | 363 | 158 | 52.00 |
Current Assets | -8.9% | 134 | 147 | 93.00 | 108 | 128 | 151 | 169 | 188 | 216 | 242 | 271 | 297 | 320 | 336 | 208 | 362 | 156 | 52.00 |
Cash Equivalents | -3.0% | 56.00 | 58.00 | 42.00 | 39.00 | 34.00 | 54.00 | 56.00 | 54.00 | 67.00 | 47.00 | 37.00 | 14.00 | 36.00 | 56.00 | 64.00 | 357 | 155 | 52.00 |
Net PPE | -4.7% | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 9.9% | 42.00 | 38.00 | 38.00 | 37.00 | 41.00 | 47.00 | 46.00 | 47.00 | 52.00 | 55.00 | 37.00 | 33.00 | 22.00 | 19.00 | 6.00 | 8.00 | 5.00 | 7.00 |
Current Liabilities | 30.4% | 20.00 | 15.00 | 14.00 | 13.00 | 15.00 | 21.00 | 20.00 | 19.00 | 24.00 | 26.00 | 23.00 | 19.00 | 14.00 | 11.00 | 6.00 | 7.00 | 5.00 | 3.00 |
Shareholder's Equity | -13.1% | 117 | 134 | 82.00 | 98.00 | 116 | 133 | 152 | 173 | 196 | 219 | 251 | 281 | 308 | 327 | 343 | 355 | - | - |
Retained Earnings | -4.9% | -417 | -398 | -375 | -355 | -334 | -313 | -292 | -269 | -243 | -217 | -182 | -148 | -118 | -95.60 | -77.69 | -63.11 | -50.97 | -15.71 |
Additional Paid-In Capital | 0.3% | 534 | 533 | 458 | 455 | 453 | 450 | 447 | 444 | 440 | 437 | 434 | 429 | 425 | 422 | 420 | 418 | 4.00 | 0.00 |
Shares Outstanding | 0.0% | 52.00 | 52.00 | 37.00 | 37.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | - | - | - | - | - | - |
Float | - | - | - | 115 | - | - | - | 55.00 | - | - | - | 340 | - | - | - | 1,010 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 24.0% | -13,956 | -18,362 | -14,368 | -20,031 | -21,939 | -16,476 | -18,067 | -28,600 | -24,046 | -26,482 | -25,165 | -24,455 | -15,774 | -11,486 | -13,567 | -11,319 | -7,486 | -5,310 | -5,000 | -6,878 | - |
Share Based Compensation | -44.2% | 1,536 | 2,751 | 2,646 | 2,671 | 2,906 | 2,664 | 3,252 | 3,375 | 3,376 | 3,009 | 4,558 | 3,094 | 2,470 | 1,999 | 1,419 | 1,877 | 2,510 | 850 | 192 | 91.00 | - |
Cashflow From Investing | 132.3% | 12,249 | -37,884 | 17,175 | 24,806 | 2,322 | 14,507 | 19,808 | 16,729 | 43,242 | 35,697 | 48,200 | 3,474 | -6,648 | 4,597 | -279,640 | - | -2.00 | -11.00 | 2.00 | -10.00 | - |
Cashflow From Financing | -100.1% | -46.00 | 71,927 | - | 51.00 | -28.00 | 52.00 | - | 153 | - | 64.00 | 184 | 481 | 830 | 270 | - | 213,844 | 83,495 | 44,331 | -70.00 | - | - |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 59,350 | $ 64,437 |
General and administrative | 27,110 | 28,391 |
Total operating expenses | 86,460 | 92,828 |
Loss from operations | (86,460) | (92,828) |
Other income (expense): | ||
Interest income | 1,924 | 2,031 |
Other income (expense) | 2,094 | (354) |
Gain on sale of IP | 0 | 2,232 |
Total other income (expense), net | 4,018 | 3,909 |
Equity in losses of unconsolidated entities | 0 | (2,250) |
Net loss | $ (82,442) | $ (91,169) |
Net loss per share, basic (in dollars per share) | $ (1.88) | $ (2.52) |
Net loss per share, diluted (in dollars per share) | $ (1.88) | $ (2.52) |
Weighted average common shares outstanding, basic (in shares) | 43,954,649 | 36,325,586 |
Weighted average common share outstanding, diluted (in shares) | 43,954,649 | 36,325,586 |
Comprehensive loss: | ||
Net loss | $ (82,442) | $ (91,169) |
Other comprehensive (loss) income: | ||
Change in unrealized (loss) gain on investments, net | 1,797 | (1,410) |
Comprehensive loss | $ (80,645) | $ (92,579) |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 56,221 | $ 34,315 |
Investments | 75,179 | 88,492 |
Prepaid expenses and other current assets | 2,634 | 4,899 |
Total current assets | 134,034 | 127,706 |
Property and equipment, net | 1,730 | 2,587 |
Restricted cash | 823 | 1,168 |
Right-of-use assets | 21,980 | 24,794 |
Total assets | 158,567 | 156,255 |
Current liabilities: | ||
Accounts payable | 2,324 | 1,877 |
Accrued expenses and other current liabilities | 17,322 | 13,384 |
Total current liabilities | 19,646 | 15,261 |
Non-current operating lease liability | 22,185 | 25,299 |
Total liabilities | 41,831 | 40,560 |
Commitments and contingencies (Note 12) | 0 | 0 |
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 10,000,000 shares and 10,000,000 shares authorized at December 31, 2023 and 2022, respectively; no shares issued or outstanding at December 31, 2023 and 2022 | 0 | 0 |
Common stock; $0.0001 par value; 500,000,000 shares authorized at December 31, 2023 and 500,000,000 shares authorized at December 31, 2022; 51,645,557 shares issued and outstanding at December 31, 2023 and 36,434,297 shares issued and outstanding at December 31, 2022 | 7 | 5 |
Additional paid-in capital | 534,187 | 452,503 |
Accumulated other comprehensive (loss) income | (27) | (1,824) |
Accumulated deficit | (417,431) | (334,989) |
Total stockholders' equity | 116,736 | 115,695 |
Total liabilities and stockholders' equity | $ 158,567 | $ 156,255 |